DrugPatentWatch Database Preview
Drugs in Development Information for Dalotuzumab
» See Plans and Pricing
What is the drug development status for Dalotuzumab?
Dalotuzumab is an investigational drug.
There have been 13 clinical trials for Dalotuzumab.
The most recent clinical trial was a Phase 2 trial.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Colorectal Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Alliance for Clinical Trials in Oncology, and National Cancer Institute (NCI).
Summary for Dalotuzumab
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (1969-12-31) |
| Vendors | 2 |
Recent Clinical Trials for Dalotuzumab
| Title | Sponsor | Phase |
|---|---|---|
| A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | Merck Sharp & Dohme Corp. | Phase 2 |
| A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) | Merck Sharp & Dohme Corp. | Phase 2 |
| Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) | Merck Sharp & Dohme Corp. | Phase 1 |
Clinical Trial Summary for Dalotuzumab
Top disease conditions for Dalotuzumab
Top clinical trial sponsors for Dalotuzumab
US Patents for Dalotuzumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
